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ABSTRACT
Background: Endoscopic management of upper urinary tract transitional cell carcinoma has
assumed an important role in diagnosis and treatment. The introduction of small diameter rigid
and flexible ureteroscopes has permitted access to the upper tract. Biopsy techniques have
been developed for accurate diagnosis and the addition of lasers has given the urologists an
excellent tool for treatment.
Methods: Medical literature available relative to the endoscopic laser treatment of upper tract
neoplasms has been reviewed.
Results: Ureteroscopic treatment has been characterized by good success with high
recurrence rates, both in the upper tract and the bladder. Bladder recurrence rates are similar to
those seen after surgical treatment of upper tract tumors. Surveillance has been ureteroscopic
since the other diagnostic options are inadequate. The holmium and neodymium:YAG lasers
are the devices most commonly used now for the endoscopic treatment of upper tract tumors.
Conclusion: Ureteroscopic treatment of upper tract neoplasms usually with ablation and
resection using the neodymium and holmium:YAG lasers is a current acceptable procedure.
This should be reconsidered as one of the options in tumor treatment.
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Transitional cell carcinoma of the upper urinary tract is an uncommon lesion but is a
potentially lethal tumor requiring treatment. Treatment has traditionally been surgical, either with
nephroureterectomy or for low grade distal ureteral tumors, distal ureterectomy, including a wide
bladder cuff around the orifice. 1,2
The development of small, rigid and flexible ureteroscopes in the early 1980’s became
possible with the introduction of fiberoptic illumination and imaging. These instruments have
permitted routine access to the entire upper collecting system3 and have revolutionized the
treatment of calculi and neoplasms. The Holmium:YAG and the Neodymium:YAG lasers are
both effective for neoplasms and can be delivered through small flexible fibers.4,5

INSTRUMENTS
Endoscopes
Small rigid endoscopes are available in single and dual channel designs ranging from
approximately 5 to 9+French tip diameter (most commonly ~7F with a 3.6F channel).6 Dual
channel designs allow for simultaneous irrigation and placement of a working device. These
endoscopes can be passed easily under direct vision into the distal ureter to inspect that area
without any prior instrumentation (i.e. termed the “no touch” inspection technique), but cannot
adequately inspect the renal pelvis or intrarenal collecting system.
Actively deflectable, flexible ureteroscopes were developed to access the intrarenal
collecting system and proximal ureter atraumatically. They are available in single channel
designs from 7.4 to 9+F while a larger endoscope is available with dual channels. The smaller
diameter endoscopes can also be placed under direct vision frequently without trauma of
guidewire introduction, thus, employing a “no touch” technique. To inspect the lower pole calyx
in most kidneys, the ureteroscope must deflect 170o but to compensate for loss of deflection
with working instruments in the channel, the active tip deflection has been increased to nearly
300o in most ureteroscopes.

3

Recently, flexible ureteroscopes have been constructed with digital imaging chips at the
tip. These produce an excellent endoscopic image with better resolution but suffer from a larger
overall diameter of nearly 10F as well as limited deflectability. Although it has been suggested
that these instruments will have greater durability, this remains to be demonstrated.

Lasers
The Holmium and Nd:YAG lasers are effective devices for treating neoplasms
throughout the urinary tract. The characteristics of these lasers are listed in Table 1. The
Nd:YAG at a wavelength of 1064 nm destroys tissue with coagulation. It has a depth of
penetration up to several millimeters (5-10) in tissue or water and therefore, direct contact of
the fiber with the neoplasm is not necessary. It is effective in treating tumors up to centimeters
in diameter. However, it is difficult to judge the depth of penetration during treatment. It can be
combined with techniques to remove the coagulated tissue.
The Holmium YAG laser is a pulsed device with a wavelength of 2100 nm. It can cause
coagulation at lower energies and higher pulse durations and can ablate the tissue coagulated
either with the holmium or the Nd:YAG laser. The Holmium energy penetrates tissue only <0.4
mm and therefore its effect is relatively superficial and is endoscopically visible.
Fibers of various sizes can be used with either laser. Each fiber consists of a central
core and a cladding with resultant diameter and deflection characteristics. The most commonly
used fibers are 200 or 365µ diameter. The smaller fiber is more flexible but is a less efficient
ablator of tissue since it has an exponentially smaller spot size, and, with the holmium:YAG, a
much smaller vaporization bubble.
Other lasers, like the diode and the thulium, can be delivered with flexible fibers but have
not yet been used and/or reported in significant clinical series of patients with upper urinary tract
urothelial tumors.
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Biopsy Devices
Tissue samples can be taken with several different devices, indwelling baskets, forceps,
graspers, snares and brushes. The most effective basket is a stainless steel flat wire design
which can be closed to trap the tissue in the angle between the wires.
Several designs of 1 mm diameter cup forceps are available and are useful in sampling
flat or solid, nonpapillary lesions with a small sample fully contained within the cup, the device
can be withdrawn through the working channel and replaced to obtain multiple tissue fragments.
The stiffness of the shaft of the forceps often prohibits endoscope deflection of more than 90 to
100o depending on the endoscope used. The other instruments are relatively ineffective in
obtaining tissue and are rarely used.

TECHNIQUES
Suspected upper tract neoplasms are often evaluated with contrast CT scan, (CT
urogram, CTU), intravenous pyelogram or retrograde ureteropyelogram. The suspected lesion is
then diagnosed endoscopically. The appearance is similar to that of urothelial tumors within the
bladder and may be papillary, sessile or flat. In one series, visual inspection alone was only
70% accurate in determining the malignancy or grade of a neoplasm in the upper tract.7
It is also important to obtain a sample of tissue for pathologic diagnosis, since the grade
of the tumor is important in the decision process for treatment. Papillary lesions can be sampled
with a stainless steel flat wire basket which is applied around the tumor and closed snugly but
not completely. It is then used to avulse a piece of tissue. The entire unit of tumor, basket and
endoscope are removed to preserve the largest piece of tissue available. Samples should not
be withdrawn with a basket through the channel since most of the sample would be sheared off
and lost.
Alternatively, for smaller, sessile or flat lesions, a cup forceps is used. Multiple samples
should be taken. If the entire sample is contained within the cup, it can be withdrawn through
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the channel of the ureteroscope. If there is a larger piece extending beyond the extent of the
cup, then again the entire unit of tumor, forceps and endoscope should be removed to maintain
the largest sample.
The tissue sample is delivered directly into a collection tube with a small aliquot of
saline. If there will be a delay in delivering the sample to the cytopathology laboratory, the
appropriate amount of cytologic preservative is added. All tissue samples are processed as
cytology specimens to avoid loss of tissue in preparation.8 A cell block can be made for
macroscopically visibly evident samples.
After adequate sampling, the tumor can be treated. Very small (1 to 2 mm) lesions can
be treated effectively and completely with the holmium laser using few pulses. We commonly
prefer to use the holmium laser for all ureteral lesions because of the lower risk of ureteral
stricture with this controlled energy source. Localized tissue reaction with subsequent stricture
may result from treatment of larger lesions or those encompassing more than one-half
circumference of the ureter or from the use of the neodymium:YAG laser which causes a deeper
tissue effect. (Table 1)9
Specific capabilities of the Ho or Nd:YAG lasers can be utilized to maximize coagulation
or ablation of neoplasms throughout the bladder or upper tract. Selection of the laser depends
on the size and location of the lesion. The holmium laser alone can coagulate tumors with the
maximum coagulative effect given by defocussing the laser beam on the tissue. Close
approximation of the tip of the fiber or contact with the tissue gives a more ablative effect and
removes tissue. Generally, there is less bleeding with the coagulative technique.
Specific holmium lasers have variable pulse durations which can be employed to obtain
unique tissue effects. The longer pulse provides the same energy per pulse giving less intensity
and improved coagulation. It retains some ablative properties while the shorter pulse duration
maximizes the ablative effect.
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The Neodymium YAG laser is a continuous wave device producing a wavelength which
penetrates more deeply into tissue. Its major effect is coagulative and is very useful for deeper
coagulation of larger tumors. It produces no ablation and the resultant coagulated tissue can be
removed mechanically or with a Ho laser. Care must be taken with the Nd:YAG laser to avoid
treating the ureteral wall circumferentially since it penetrates deeply and can result in a stricture.
Within the renal pelvis, the energy choice depends mainly upon the size of the lesion.
Larger vascular tumors (>1 cm) can be coagulated initially with the neodymium:YAG and then
ablated and cleared with the holmium when a combination laser is available. These lesions can
also be treated with the holmium laser alone. Lower holmium energy tends to maximize the
coagulative effect and minimize the risk of bleeding (e.g. 0.5 to 0.6 joules and 5 hertz). When a
laser with a variable pulse duration is available, the longer duration is used to maximize the
coagulative effect and minimize bleeding.
Adequate removal of neoplastic tissue without penetration of the pelvis or the ureter is
highly technique dependent. The fiber of the holmium laser is applied only where the
coagulative or ablative effect is desired. When the tumor partially obscures the ureter or renal
pelvis, the laser is moved in an arc along the normal contour at the base of the neoplasm. It is
helpful to initiate resection at the more proximal portion of the tissue and then work distally. In
this way, it is possible to avoid advancing the fiber into the mucosa or wall of the ureter or renal
pelvis.
Some intrarenal locations are inherently difficult to treat with lasers. This occurs most
commonly on the medial wall of the lower infundibulum. In these unusual situations, if it is
impossible to reach with the 200 micron fiber, the flexible ureteroscope may deflect further with
a 2F Bugbee electrode. This device also has the advantage of coagulation from the side of the
tip. As opposed to laser fibers, it is not necessary to point the device directly at the tissue.
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CLINICAL RESULTS
Several papers have summarized reports of ureteroscopic treatment of upper tract
transitional cell carcinoma (UUTTCC).10,11,12 Many of these papers have used lasers as one of
the endoscopic ablative devices for treatment. The earliest series, before the availability of the
holmium laser, used electrocautery or electroresection while some were limited to rigid
endoscopes. These reports are characterized by a high success rate for ablation of tumor with
preservation of renal units. However, there is a high recurrence rate of the neoplasms. Kidneys
have been preserved in approximately 70% of patients, while recurrences have ranged from 2088%. Therefore, endoscopic surveillance has an essential role in the treatment and follow up
process after ureteroscopic treatment of UTTCC.
New or recurrent bladder tumors are also common after the treatment of an upper
urinary tract carcinoma (Table 2). New or recurrent bladder tumors were seen after
ureteroscopic treatment in 40.5% of patients in series up to 2001.13 Among more current series,
there is also a wide range of bladder tumors appearing in 20-44% of patients. In comparison,
bladder tumors have been reported to occur in from 15 to 45% of patients treated with open
surgical nephroureterectomy and from 10 to 55% after laparoscopic nephroureterectomy. It is
difficult to make direct comparisons, since the grade and stage of tumors, the intensity of
endoscopic follow up and particularly the duration of follow up varies so widely. The rate of
bladder tumors from these rough comparisons suggests that the rate of new or recurrent
bladder tumors after endoscopic resection is not out of the range seen with
nephroureterectomy.
By far the most common complication after ureteroscopic treatment is ureteral stricture.
This can occur either at the site of resection of a ureteral tumor or at other sites throughout the
ureter. In a combined series a rate of 13.7% was reported in 2001.13 It is impossible to separate
the strictures occurring in patients treated with lasers since all series include some treated with
electrofulguration. The overall stricture rate in the series available is 12.7%, which is
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considerably higher than the rate of <1% seen after the ureteroscopic treatment of ureteral
stones.30 (Table 3)

DISCUSSION
The standard treatment of upper tract neoplasms has been nephroureterectomy with
excision of a bladder cuff. Studies in the 1970’s demonstrated the feasibility of distal
ureterectomy to treat low grade distal ureteral neoplasms. Therapy was less successful for renal
pelvic and proximal ureteral lesions suggesting a “downstream” effect.31,32
The next developmental step was to treat upper urinary tract tumors endoscopically.
Based on the established endoscopic treatment of bladder tumors, the application of these
techniques became limited only by the instrumentation available. This concept became a reality
as appropriate ureteroscopes became available.33,34 The refinement of these endoscopes has
made it possible to reach the entire intrarenal collecting system in most patients.
Similarly, instruments and techniques were developed to sample and treat upper tract
tumors. Accurate diagnosis has improved by using cytologic techniques with cell blocks to
identify larger samples.35,36 Ureteroscopic biopsies have been shown to have a high, but not
perfect accuracy ranging from 80 to 90%.37,14
Endoscopic access to the upper tract presents the opportunity for treatment. The first
instruments for ablation and coagulation were 2 or 3F electrodes. In the series cited, patients
dating from the early 1980’s were treated electrosurgically and often subsequently grouped with
and then treated with lasers as they recurred during long term follow up. Both the holmium:YAG
and neodymium:YAG lasers can be delivered through small flexible fibers to the vast majority of
surfaces within the upper collecting system.
The Neodymium:YAG laser has been demonstrated to be an effective mechanism for
the endoscopic treatment of bladder tumors. In a small series, it was shown to coagulate upper
tract neoplasms successfully with an open surgical approach.38 The Neodymium:YAG laser can
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effectively coagulate tissue, but it may be difficult to determine the depth of coagulation and the
treated tissue remains in place and is not cleared. This is a minimal problem in the bladder but
in the ureter or the renal pelvis, the coagulated tissue obscures deeper portions of the tumor
which may be viable. This treated tissue must be removed mechanically or by ablation with the
holmium laser. The holmium:YAG laser can also coagulate tissue primarily, although less
efficiently. Lengthening the holmium pulse duration improves the coagulative effect. Combining
the Ho and Nd:YAG lasers gives maximal coagulative and ablative effects, delivering a more
controlled coagulation and ablation of urothelial tumors than that delivered with a small cautery
electrode.
The aim of the conservative management of upper tract neoplasms is to preserve renal
function. This may be considered imperative or strongly indicated in patients with a solitary
kidney, solitary functioning kidney or limited renal function. The alternative of
nephroureterectomy with subsequent dialysis, and even possible later transplantation, must be
considered and offered to the patient. There is a high morbidity and also mortality associated
with dialysis. In a recent series of 128 hemodialysis patients with a mean age of 61 years, the 3
year survival was only 55%.39 Data from end stage renal disease database shows a decrease
in survival in older patients.40 Five year survival over the last cited year (2001) was 30.7% for
patients ages 65-69, 20.2% for those 70-79 and dropped to 9.6% at ≥ 80 years.
Recently, the risks of chronic renal failure associated with a solitary kidney have become
evident.41 There is interest in for maintaining renal function and avoiding development of an
anephric state. Much of this emphasis has been directed toward the development of
laparoscopic partial nephrectomy. However, the same arguments can be applied to UUTTCC.
The treatment of upper tract neoplasm with ureteroscopic techniques is quite successful.
Low grade tumors carry a low mortality with treatment by many means including ureteroscopy.
High grade tumors have a more pessimistic prognosis in general, with lower survival rates after
either nephroureterectomy or endoscopic treatment. When high grade tumors are treated
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ureteroscopically, often palliatively, most patients maintain renal function with acceptable local
control. Overall, ureteroscopic treatment of upper tract tumors has an excellent disease specific
survival and results in approximately 70% renal maintenance.42
There are also both recognized and potential risks from ureteroscopic treatment. There
remains a very high recurrence rate in most series ranging from 20 to 85%. Generally, the more
recent reports have higher recurrence rates. This may be related to the longer follow up in these
series. Alternatively, it may be related to the treatment of larger and more proximal neoplasms
which in a surgical series have been shown to be more likely to have distal recurrences. The
progression of grade is also possible approximating 10% in a large series. Therefore, it is
essential that treated patients have endoscopic follow up since the noninvasive modalities of
urinalysis, urinary cytology or FISH studies are inadequate to define recurrence.43,44,45
Cost has become an important consideration in guiding treatment. Repetitive treatment
or repetitive endoscopic surveillance can be an ongoing expense for health systems. In the US,
the high cost associated with transplantation, or the even greater costs of hemodialysis makes
endoscopic treatment and surveillance an attractive alternative. In comparison, in the medicare
payment system, hemodialysis was the most expensive while successful ureteroscopic
treatment with surveillance was the least expensive. There can be expected to be variations in
different national health systems.42
There remain many unknown factors involved in the endoscopic therapy of upper tract
TCC. For example, it is impossible to determine the exact stage of the neoplasm. Several
series have shown that the stage is related to the grade.46 The latter can be obtained from
ureteroscopic biopsy with a reasonably high accuracy when compared with the grade seen on
surgical specimens. Other staging studies, such as CT scanning, can be useful but do not have
sufficient resolution for lower stages. Currently, tumor grade remains the best prognosticator.
The sources of urothelial tumor recurrences are unknown. It may be related to the field
change in patients with urothelial carcinoma. This is supported from the known 5 to 10%
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bilaterality of upper tract neoplasms. Similarly, the high risk of new or recurrent tumors at similar
rates after ureteroscopic treatment or open or laparoscopic nephroureterectomy suggests a field
change rather than seeding. However, cytologically intact cells can be seen in the irrigant after
endoscopic laser treatment.47 Their role in recurrence is unknown. Another unknown is the
process of treatment itself. It is impossible to determine the adequacy of coagulation and
ablation visually. For example, the depth of penetration from the neodymium:YAG laser is
never certain except by visual inspection, which is inadequate. Similarly, the extent or presence
of invasion of the neoplasm is impossible to determine.
Adjuvant therapy has been considered as a means to reduce recurrence. Agents such
as topical Mitomycin, used after endoscopic resection, may have a role in decreasing
recurrence in the upper tract as it has in the bladder.48 It has been employed in two short
series.49,50 It has been demonstrated to be tolerated but there are insufficient data to determine
its efficacy.

CONCLUSION
Currently, ureteroscopic laser resection of upper tract neoplasms is an acceptable option
for treatment. It is an excellent first choice for patients with a solitary kidney, compromised
contralateral kidney or impaired renal function. It has been used with very good success
electively in patients with small low grade tumors and a normal contralateral kidney in an effort
to preserve renal function. All patients must be followed endoscopically and must be willing to
agree to endoscopic surveillance because of the high risk of recurrence in the upper tract and
bladder. The holmium and neodymium:YAG lasers are presently the most commonly used
devices. The laser combining Nd and Holmium:YAG is convenient and effective but the
holmium:YAG lasers can be used alone, preferentially with the variable pulse duration.
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Table 1
Use of Ho and ND:YAG Laser for
Ureteroscopic Treatment of UTTCC*
Laser
Ho
Nd
Ho & Nd

Kidney
8
2
34

Site
Ureter
40
-2

Bladder
5
6
22

Total 77 procedures (some with > 1 site)
Over 1 year (11/08 – 11/09)
*D Bagley unpublished
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Table 2

New or Recurrent Bladder Tumors:
After Ureteroscopic Treatment of UUTTCC
Reference

Bladder Tumor

%

Sowter et al16*

12/35

34.3

Thompson et al15

37/83

44.6

Daneshmand et al14

6/30

20.0

Chen & Bagley13o

41/101

40.5

Combined
*No history BT
o
reviewed series to 2001

96/249

38.5

After Laparoscopic or Open Nephroureterectomy for UUTTCC
%
%
Laparoscopic
Open
Reference
Rassweiler17
24.0
24.7
Wolf18
55
-Okegawa19
20
17
Tsujihata20
28
33
Raman 21
29
35
Chung22
44
36
Manabe23
32.8
38.0
Muntener24
41
-Roupret25
10
15
Taweemonkongsap26
29
45
Waldert27
26
27
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Table 3
Strictures after Ureteroscopic
Treatment of UUTTCC
Reference
Suh et al28
Daneshmand et al14
Johnson et al29
Sowter et al16
Chen et al13*
Overall

Patient
16
30
35
40
139
260

Stricture
2
5
3
4
19
33

%
12.5
16.7
8.5
10.0
13.7
12.7

*combined series to 2001

19

